RT Journal Article
SR Electronic
T1 Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 12S
OP 22S
DO 10.2967/jnumed.121.262750
VO 62
IS Supplement 3
A1 George Sgouros
A1 Yuni K. Dewaraja
A1 Freddy Escorcia
A1 Stephen A. Graves
A1 Thomas A. Hope
A1 Amir Iravani
A1 Neeta Pandit-Taskar
A1 Babak Saboury
A1 Sara St. James
A1 Pat B. Zanzonico
YR 2021
UL http://jnm.snmjournals.org/content/62/Supplement_3/12S.abstract
AB Radiopharmaceutical therapy (RPT) is defined as the delivery of radioactive atoms to tumor-associated targets. In RPT, imaging is built into the mode of treatment since the radionuclides used in RPT often emit photons or can be imaged using a surrogate. Such imaging may be used to estimate tumor-absorbed dose. We examine and try to elucidate those factors that impact the absorbed dose–versus–response relationship for RPT agents. These include the role of inflammation- or immune-mediated effects, the significance of theranostic imaging, radiobiology, differences in dosimetry methods, pharmacokinetic differences across patients, and the impact of tumor hypoxia on response to RPT.